Grant: Alliance Grants
University of Waterloo
$53,846.00
A point-of-care, microfluidics-based approach for multiplexed detection of biomarkers in unprocessed blood using a surface plasmon resonance sensor _x000d_
EF 2020-21
Résumé
Affinité Instruments, a Montréal-based start-up, is developing a low-cost, point-of-care (POC) device for rapid detection of COVID-19 antibodies using whole blood sample. As the relationship between antibodies and immunity to infection with the novel severe acute respiratory syndrome coronavirus (SARS-COV-2) is still unknown, detection of antibodies can be used to assess previous exposure to pathogens.
In the proposed project, the detection of antibodies will be performed by using a surface plasmon resonance (SPR) device integrated with a microfluidic sample preparation platform. The SPR device is a key bioanalytical method in biosensing application, antibody characterization, and drug discovery and development. SPR sensor that is functionalized with anti-human immunoglobin (IgG, IgM, and IgA) antibodies can be used to detect anti-SARS-CoV-2 antibodies in the nanomolar range. To develop a next-generation SPR product for clinical testing of COVID-19 antibodies, there is a need to design a customized microfluidic platform to separate plasma from whole blood to enable direct blood testing. In this project, Affinité Instruments teams up with Poudineh group (expert in microfluidic device design and fabrication for biomedical application) at the University of Waterloo to develop a custom designed microfluidic platform that can be integrated with SPR sensor. Using a plasma separation membrane, the pump-free microfluidic filtration device will separate plasma in less than 10 min. The collected plasma will be directly sent to SPR which will determine the levels of COVID-19 antibodies in the blood. The proposed POC device will offer a rapid diagnosis in less than 10 min from whole blood and will be more accurate than any existing testing technologies. This novel detection technology will limit the spread of virus and the success of this study will have potential impact in recovering Canadian and global economies.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
556618-2020
Name nom
Poudineh, Mahla
Department département
Electrical & Computer Engineering
Organization id
33
Institution établissement
University of Waterloo
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2020
Competition year année de concours
2020
Award amount
53846
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Installment
inst:1 - 1
Partie
1
Nb partie
1
Application title
A point-of-care, microfluidics-based approach for multiplexed detection of biomarkers in unprocessed blood using a surface plasmon resonance sensor _x000d_
Keyword
NSERC
Application summary
Affinité Instruments, a Montréal-based start-up, is developing a low-cost, point-of-care (POC) device for rapid detection of COVID-19 antibodies using whole blood sample. As the relationship between antibodies and immunity to infection with the novel severe acute respiratory syndrome coronavirus (SARS-COV-2) is still unknown, detection of antibodies can be used to assess previous exposure to pathogens.
In the proposed project, the detection of antibodies will be performed by using a surface plasmon resonance (SPR) device integrated with a microfluidic sample preparation platform. The SPR device is a key bioanalytical method in biosensing application, antibody characterization, and drug discovery and development. SPR sensor that is functionalized with anti-human immunoglobin (IgG, IgM, and IgA) antibodies can be used to detect anti-SARS-CoV-2 antibodies in the nanomolar range. To develop a next-generation SPR product for clinical testing of COVID-19 antibodies, there is a need to design a customized microfluidic platform to separate plasma from whole blood to enable direct blood testing. In this project, Affinité Instruments teams up with Poudineh group (expert in microfluidic device design and fabrication for biomedical application) at the University of Waterloo to develop a custom designed microfluidic platform that can be integrated with SPR sensor. Using a plasma separation membrane, the pump-free microfluidic filtration device will separate plasma in less than 10 min. The collected plasma will be directly sent to SPR which will determine the levels of COVID-19 antibodies in the blood. The proposed POC device will offer a rapid diagnosis in less than 10 min from whole blood and will be more accurate than any existing testing technologies. This novel detection technology will limit the spread of virus and the success of this study will have potential impact in recovering Canadian and global economies.